Agios is hoping for a broad label in thalassemia, covering both alpha and beta subtypes regardless of transfusion dependence. They estimate that this market (18+) is 6,000 in the US. Interestingly ...
The risk of venous thromboembolism (VTE), or blood clots, in individuals with sickle cell trait (SCT) is higher than in individuals without the trait. However, the risk is lower than for those with ...
Are you searching for medications to treat 'Thalassemia'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Thalassemia. The page includes both ...
Below, I explain the strategy, and how we are applying it not only in cystic fibrosis, but also in sickle cell disease, beta thalassemia, alpha-1-antitrypsin deficiency, APOL1-mediated kidney ...
The portable alpha strategy focuses on investing in stocks or other assets that have demonstrated little or no correlation with the markets. To do this, investors separate alpha from beta by ...